Is Gilead Sciences Inc (NASDAQ:GILD)’s Idelalisib Free From The Trial Phase?
Gilead Sciences, Inc (NASDAQ:GILD) has stalled the idelalisib Phase-III clinical-trial before the scheduled date. This is due to the fact that an Independent Data-monitoring Committee has taken an interim peek at the study data and has shown that the idelalisib, the company’s PI3k-delta inhibitor in conjunction with Rituxan by Roche was working more effectively than the latter by itself. This was being used in patients who had been previously treated for chronic lymphocytic leukemia.
The norm is that Data Monitoring Committees recommend the early end of trails in the event that there is unequivocal-evidence that the medication is working. In such cases, it is not ethical to continue the trial with a group that is also receiving an inferior drug-regimen. Now that the trail has come to an end, the patients who choose to be treated with idelalisib can get the opportunity to do so.
In Thursday’s trading, Gilead Sciences, Inc (NASDAQ:GILD) rose by 6.52%. The opening price of the shares was $61.63, which climbed to an intraday high of $62.80 and dipped to a close of $62.74. Approximately 15.24 million shares were traded on Thursday while an average volume of 6.67 million shares were traded over a 30 day period. The 52-week low of Gilead Sciences, Inc (NASDAQ:GILD) shares is $32.07 and its 52-week high is $64.74. The company has a market capitalization of $96.03 billion.
About the company
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based bio-pharma company. It is involved in discovering, developing and commercializing medicines. It focuses on areas such as human immunodeficiency virus (AIDS), liver diseases like hepatitis-B and C and metabolic or respiratory conditions. Gilead Sciences, Inc (NASDAQ:GILD) has operations in North America, Asia Pacific and Europe. It’s products include Truvada, ,Atripla, Complera/Eviplera, Tamiflu Viread, Hepsera, Letairis, Emtriva, Ranexa, Lexiscan/Rapiscan, Vistide, Macugen, AmBisome, Cayston.